Controlling growth of organic crystals with high-powered magnets could have major benefits for pharmaceutical development
Press release issued: 17 November 2017
A Bristol-led, international project investigating a new method of controlling the growth of organic crystals, with potential benefits for pharmaceutical development, has taken a step forward with the opening of a new £1 million laboratory.
The MagnaPharm project, funded under the EU Horizon 2020 'Future and Emerging Technologies' programme, aims to improve the efficacy of pharmaceutical compounds by crystallising them in high magnetic fields.
The ability to do this would have a transformative effect on almost all pharmaceutical compounds making them more effective in terms of getting into the bloodstream faster and better.
The new laboratory - one of only few of its kind in the UK - was officially opened this week.
It features four high-field electromagnets to enable crystallisation experiments under fields of over 3T.
With these electromagnets, Bristol will be able to act as a high-throughput screening centre for all the pharmaceutical targets under investigation.
The project initially targets 12 of the most high-profile, high-worth generic drugs with the aim of uncovering new crystal forms of them.
Dr Hall said: "The application of magnetic fields to intentionally control variations in the crystal structure of pharmaceuticals is entirely novel and opens up the possibility producing drugs which are more effective.
"One can imagine, for example, being able to take a lower dose of a drug to get the same effect, or even to enable new drugs which have stalled in development due to solubility issues, to come to market."